GLP-1 / GIP / Glucagon Receptor Mechanism Map
A mechanism-side view that complements the GLP-1 hub. For receptor-by-receptor pharmacology and regulatory framing, see the GLP-1 hub itself.
Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.
Pathway background
The incretin axis is the gut-to-pancreas hormonal arc that produces the characteristic exaggerated insulin response to oral (versus intravenous) glucose loads. Two hormones — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — are secreted from intestinal endocrine cells in response to nutrient ingestion. Both amplify the β-cell insulin response in a glucose-dependent manner. Glucagon, secreted from pancreatic α-cells, opposes insulin and drives hepatic glucose output and energy expenditure.
Modern incretin pharmacology exploits the receptor specificity and residence time of synthetic peptide agonists to produce clinically-meaningful glycaemic control and weight reduction. The progression from mono- to dual- to triple-agonism reflects a strategy of layering complementary receptor effects: GLP-1 alone covers β-cell insulin response and satiety; GIP adds adipocyte modulation and possibly nausea offset; glucagon adds energy expenditure and hepatic lipid effects.
Receptors at a glance
- GLP-1 receptor — β-cell insulin secretion, gastric emptying, hypothalamic satiety.
- GIP receptor — β-cell co-stimulation, adipocyte modulation, possible nausea offset.
- Glucagon receptor — hepatic glucose output, lipolysis, energy expenditure.
Agonist generations
- Mono — semaglutide, liraglutide, exenatide. GLP-1R only. Established benefit in type-2 diabetes and obesity.
- Dual — tirzepatide (GIPR + GLP-1R). Superior weight reduction vs semaglutide in head-to-head trials (SURPASS-2).
- Triple — retatrutide (GIPR + GLP-1R + GCGR). Phase II data show further-improved weight reduction; not yet approved anywhere.
Mono → dual → triple as a pharmacological strategy
It is worth distinguishing a polypharmacological molecule — a single agent that activates multiple receptors — from a “stack” of separate agents combined by a researcher. Tirzepatide is one molecule with dual activity, designed and tested as a single drug. Retatrutide is one molecule with triple activity. Stacking separate GLP-1 and GIP agonists would be a different exercise with a different (and largely unstudied) pharmacological profile and side-effect risk.
The pharmacological rationale for layered receptor agonism is that each receptor contributes a complementary effect: GLP-1R drives satiety and glycaemic control; GIPR may reduce GLP-1-driven nausea and add adipocyte effects; GCGR adds energy expenditure. The clinical trial record so far supports the layering — dual outperforms mono, and early triple data outperforms dual — but every additional receptor adds biological complexity that needs to be characterised in safety terms.
Evidence status
Human evidence: the strongest in any peptide class on this site. SURPASS (tirzepatide in T2D), SURMOUNT (tirzepatide in obesity), and the Phase II retatrutide programme are large, well- designed, multi-region trials with clinically-meaningful endpoints. Mono-agonists (semaglutide) have multi-year cardiovascular outcomes data.
Translation caveats: trial populations and trial durations constrain what the evidence supports. Off-label aesthetic use, athletic use, or use in populations excluded from the trials (pregnancy, severe psychiatric history) is not supported by the clinical record. See clinical trial evidence vs online claims.
Regulatory sensitivity
All licensed agents in this class are prescription-only medicines where they hold authorisation. The class is among the most actively regulated and enforcement-prioritised in the UK currently. See: POM advertising rules and UK weight-loss medicine advertising caution.